By Malcolm Stacey | Thursday 14 February 2019
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Hello Share Tasters. I now always add a warning to any piece I do on medical pioneers. Rewards can be huge if a new drug comes on the market, but the licensing authorities have understandably to be very cautious. A share which I commended to your further research a month ago has just suffered a huge disappointment. US regulators have currently rejected the company’s new iclaprim drug…
Join us for free and gain access to three articles per month
Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.
Filed under:
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Time left: 20:14:10